Dendreon Corp reaches Stalking-Horse Agreement with Valeant for Provenge
Dendreon Corp that filed for bankruptcy has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc.
FDA approves Evotaz for Treatment of HIV-1 Infection
On Thursday, pharmaceutical major Bristol-Myers Squibb announced that the United States Food and Drug Administration panel has approved its Evotaz tablets for the treatment of HIV-1 infection in adult
AstraZeneca to use CRISPR genome-editing technology for key therapeutic areas
On Thursday, British drug maker AstraZeneca disclosed about its four research agreements, which will allow the company to develop and deliver a new generation of medicines for a range of diseases.
Gavi looks forward to vaccinate millions more children
Gavi, the Vaccine Alliance is looking for funds to expand its early childhood vaccine program in developing countries.
Major Clinical Trial Success for Astrazeneca Heart Drug
According to a major clinical trial, Brilinta, the blood-thinning drug by AstraZeneca largely reduces the risk of death or heart attack in patients who have a history of previous attacks.
Shire buys rival NPS Pharmaceuticals
Shire Plc announced that it has agreed to a multibillion-dollar purchase of NPS Pharmaceuticals Inc., a biopharmaceutical company.
AstraZeneca's MedImmune enters in deal with Omnis Pharmaceuticals
AstraZeneca PLC has revealed that its biologics research and development arm MedImmune has struck a licensing deal with Omnis Pharmaceuticals.
Bristol-Myers’s Opdivo gets FDA approval for treatment of metastatic melanoma
On Monday, the US Food and Drug Administration (FDA) approved Bristol-Myers's Opdivo for the treatment of metastatic melanoma or advanced skin cancer that no longer responds to other drugs.
